Ddis-16. onc201 in combination with radiation exhibits synergistic efficacy in high grade gliomas and other advanced cancers

INTRODUCTION ONC201 is the first small molecule DRD2 antagonist for oncology that is being investigated as a single agent in advanced cancer clinical trials. Downstream of DRD2 antagonism, ONC201 activates the integrated stress response pathway and apoptosis. ONC201 has exhibited preclinical and clinical anti-tumor activity in high grade gliomas. Given that ONC201 exhibits broad synergy with anti-cancer drugs, excellent safety, and single agent activity in tumor types where radiation is used routinely, we evaluated the combination of ONC201 with radiation in solid tumors.